RECRUITING

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Description

This is a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results. The study will include adult patients with chronic (\> 1 year duration) primary Immune Thrombocytopenia (ITP) only. Patients will be identified based on a laboratory confirmed diagnosis of ITP in the medical records, where there is also a physician-confirmed diagnosis of primary ITP. If patients consent to take part in the study, a routine clinical visit will also serve as the study visit. All study participants will have a routine blood test as part of their standard clinical care at the study visit, and this same procedure will be used to collect supplementary blood samples to assess a variety of biomarkers. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.

Conditions

Chronic Immune ThrombocytopeniaPrimary Immune ThrombocytopeniaAdult Immune Thrombocytopenia
Talk to us

Related Conditions:

Chronic Immune ThrombocytopeniaPrimary Immune ThrombocytopeniaAdult Immune Thrombocytopenia

Study Overview

On this page

Study Details

Study overview

This is a multi-center, hospital based, cross-sectional study based on data from patient medical records, including laboratory results. The study will include adult patients with chronic (\> 1 year duration) primary Immune Thrombocytopenia (ITP) only. Patients will be identified based on a laboratory confirmed diagnosis of ITP in the medical records, where there is also a physician-confirmed diagnosis of primary ITP. If patients consent to take part in the study, a routine clinical visit will also serve as the study visit. All study participants will have a routine blood test as part of their standard clinical care at the study visit, and this same procedure will be used to collect supplementary blood samples to assess a variety of biomarkers. Data will be collected using a combination of chart review, clinical outcome assessment administration, and laboratory results through blood tests.

Cognitive Status, Fatigue, and Inflammation in Patients With Immune Thrombocytopenic Purpura (ITP)

Cognitive Status, Fatigue and Inflammation in Patients With Immune Thrombocytopenia (ITP)

Condition
Chronic Immune Thrombocytopenia
Intervention / Treatment

-

Contacts and Locations

Seattle

University of Washington-Fred Hutchinson Cancer Center_Site Number: 8400003, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient diagnosed with chronic (ITP with \> 1 year duration) primary ITP living in the USA or the UK:
  • * On ITP pharmacologic treatment, regardless of last platelet count (below or above 100 x 10\^9 counts/L);
  • * Patients in remission as per their most recent blood test (platelet count \>100 x 10\^9 counts/L) and without ITP-specific treatment for less than 1 year
  • * Adult patient who are 18 years or older at index date
  • * Patient who has received at least one initial first line therapy (corticosteroids \[CS\]/ intravenous immunoglobulin \[IVIg\]/ANTI d) with initial response (platelet count ≥ 50 x 10\^9 counts/L) as of index date
  • * Secondary ITP
  • * Patients in remission as per their most recent blood test (platelet count \>100 x 10\^9 counts/L) and without ITP-specific treatment for 1 year or more
  • * Patients with recent or active infection recorded 14 days or less before index date; patients with uncontrolled chronic infections or who were recently diagnosed with a chronic infection (≤14 days of index date).
  • * Patients with vaccination in 28 days before index date
  • * Patients treated with rilzabrutinib on or before index date

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sanofi,

Study Record Dates

2025-05-23